BMJ Open (Aug 2023)
Host-microbiota relationship in the pathophysiology of aseptic abscess syndrome: protocol for a multicentre case-control study (ABSCESSBIOT)
- ,
- Nathalie Costedoat-Chalumeau,
- Patrick Jégo,
- Nicolas Barnich,
- Emilie Vazeille,
- Maria Nachury,
- Marc André,
- Stanislas Faguer,
- Laurent Sailler,
- Bruno Pereira,
- Olivier Chosidow,
- Alexandre Thibault Jacques Maria,
- Jean-François Viallard,
- Arnaud Hot,
- Jean-David Bouaziz,
- Jérôme Connault,
- Jean Schmidt,
- Ludovic Trefond,
- Felix Ackermann,
- Fabrice Bonnet,
- François Lifermann,
- Nicolas Limal,
- Guillaume Cadiot,
- Elisabeth Billard,
- Richard Bonnet,
- Romain Altwegg,
- Alexandra Audemard-Verger,
- Damien Richard,
- Elisabeth Aslangul,
- Fairouzé Bani Sadr,
- Sophie Besnard,
- Jean-François Bourgaux,
- Sebastien De Almeida,
- Amandine Dernoncourt,
- Hélène Desmurs Clavel,
- Amelie Dutheil,
- Jean-Marc Galempoix,
- Camille Hua,
- Estelle Jean,
- Wendy Jourde,
- Clemence Lepelletier,
- Jean Benoit Monfort,
- Yves Poinsignon,
- Marie Laure Rabilloux,
- Jerome Razatomaery,
- Clea Rouillon,
- Mihaela Saplacan,
- Laure Swiader
Affiliations
- Nathalie Costedoat-Chalumeau
- 3 Centre de référence maladies rares, Hôpital Cochin, AP-HP, Paris, France
- Patrick Jégo
- Internal Medicine and Clinical Immunology Department, CHU Rennes, Universitaire de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
- Nicolas Barnich
- 2 U1071 Inserm, Clermont-Auvergne University, Clermont-Ferrand, France
- Emilie Vazeille
- Inserm U1071, M2iSH, USC-INRA 1382, Université Clermont Auvergne, Clermont-Ferrand, Auvergne-Rhône-Alpes, France
- Maria Nachury
- Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France
- Marc André
- 15 Internal Medicine, G. Montpied Hospital, Clermont-Ferrand, France
- Stanislas Faguer
- 13 Nephrology and Organ Transplantation, CHU Toulouse, Toulouse, France
- Laurent Sailler
- 1 Internal Medicine, University Hospital Centre Toulouse, Toulouse, Occitanie, France
- Bruno Pereira
- 2 DRCI Biostatistical department, University Hospital, Clermont-Ferrand, France
- Olivier Chosidow
- professor of dermatology
- Alexandre Thibault Jacques Maria
- 1 Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, Universite Montpellier, Medical School, Montpellier Cedex 5, France
- Jean-François Viallard
- 16 Internal Medicine Department, Hôpital Haut-Lévêque, Bordeaux University Hospital, Avenue de Magellan, Pessac, France
- Arnaud Hot
- Internal Medicine, University Hospital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
- Jean-David Bouaziz
- 1 Université de Paris, UFR de Médecine Paris Nord, Paris, France
- Jérôme Connault
- Jean Schmidt
- Internal Medicine, Amiens University Hospital, Amiens, France
- Ludovic Trefond
- Université Clermont Auvergne, CHU Clermont-Ferrand, Service de Médecine Interne, Hôpital Gabriel Montpied, INSERM U1071, Clermont-Ferrand, France
- Felix Ackermann
- 3 Department of Internal Medicine, Hopital Foch, Sursennes, France
- Fabrice Bonnet
- Department of Internal Medicine, CHU, Bordeaux, France
- François Lifermann
- 9 Service de Médecine Interne Hématologie, Centre Hospitalier de Dax, Dax, France
- Nicolas Limal
- 20 Service de Médecine Interne, Centre de Référence Labellisé pour la Prise en Charge des Cytopénies Auto-immunes de l’Adulte, Hôpital Henri Mondor, Assistance Publique–Hôpitaux de Paris, Vasculitis Clinic, Créteil, France
- Guillaume Cadiot
- Elisabeth Billard
- 1Clermont Université, ‘Microbe intestin inflammation et Susceptibilité de l`Hôte’, UMR1071 Inserm/Université d`Auvergne M2iSH, Clermont-Ferrand, France
- Richard Bonnet
- 1Clermont Université, ‘Microbe intestin inflammation et Susceptibilité de l`Hôte’, UMR1071 Inserm/Université d`Auvergne M2iSH, Clermont-Ferrand, France
- Romain Altwegg
- 18Hépato-gastro-entérologie, Hôpital Saint Eloi, Montpellier, France
- Alexandra Audemard-Verger
- Department of Internal Medicine and Clinical Immunology, CHRU Tours, University of Tours, Tours, France
- Damien Richard
- Service de Pharmacologie médicale, CHU Clermont-Ferrand, Clermont-Ferrand, France
- Elisabeth Aslangul
- Fairouzé Bani Sadr
- Sophie Besnard
- Jean-François Bourgaux
- Sebastien De Almeida
- Amandine Dernoncourt
- Hélène Desmurs Clavel
- Amelie Dutheil
- Jean-Marc Galempoix
- Camille Hua
- Estelle Jean
- Wendy Jourde
- Clemence Lepelletier
- Jean Benoit Monfort
- Yves Poinsignon
- Marie Laure Rabilloux
- Jerome Razatomaery
- Clea Rouillon
- Mihaela Saplacan
- Laure Swiader
- DOI
- https://doi.org/10.1136/bmjopen-2023-073776
- Journal volume & issue
-
Vol. 13,
no. 8
Abstract
Introduction Aseptic abscess (AA) syndrome is a rare disease whose pathophysiology is unknown. It is often associated with inflammatory bowel disease and characterised by sterile inflammation with collections of neutrophils affecting several organs, especially the spleen. Microbiota are known to influence local and systemic immune responses, and both gut and oral microbiota perturbations have been reported in diseases associated with AA syndrome. However, interactions between these factors have never been studied in AA syndrome. The purpose of this translational case-control study (ABSCESSBIOT) is to investigate gut and/or oral microbiota in patients with AA syndrome compared with healthy controls. Moreover, microbiota associated metabolites quantification and Treg/Th17 balance characterisation will give a mechanistic insight on how microbiota may be involved in the pathophysiology of AA syndrome.Methods and analysis This French multicentre case-control study including 30 French centres (University hospital or regional hospital) aims to prospectively enrol 30 patients with AA syndrome with 30 matched controls and to analyse microbiota profiling (in stools and saliva), microbial metabolites quantification in stools and circulating CD4+ T cell populations.Ethics and dissemination This study protocol was reviewed and approved by an independent French regional review board (n° 2017-A03499-44, Comité de Protection des Personnes Ile de France 1) on 10 October 2022, and declared to the competent French authority (Agence Nationale de Sécurité du Médicament et des produits de santé, France). Oral and written informed consent will be obtained from each included patient and the control participant. Study results will be reported to the scientific community at conferences and in peer-reviewed scientific journals.Trial registration number Clinical Trials web-based platform (NCT05537909).